Schering-Plough 3Q 3Q Revenues: $4.5 billion (-2%) 3Q Earnings: $515 million (-16%) YTD Revenues: $13.5 billion (-4%) YTD Earnings: $2.0 billion (+43%) Comments: Pharmaceutical sales in the quarter were $3.5 billion (+6%). Sales of Remicade were up 8% to $608 million. Sales of Temodar were $278 million (+2%). Nasonex sales were up 3% to $266 million. Pegintron sales were down 16% to $198 million. Global sales of Clarinex were $164 million (-7%). Prescription Claritin sales wer...